RYZ-801

N/A

Report date: 2025/11/21 17:41:07
NME

Base Information

Drug NameRYZ-801
Drug Alias NameRYZ-801(225Ac)RYZ-801ABZ-706225Ac-GPC3
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[4] 
Mechanisms of ActionAnti-Glypican-3Ionising radiation emitters
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPeptiDream IncRayzeBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesPeptiDream IncAibozi Pharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesRayzeBio Inc
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A